Anofi - Net Worth and Insider Trading

Anofi Net Worth

The estimated net worth of Anofi is at least $5.1 Billion dollars as of 2023-03-23. Anofi is the 10% Owner of Translate Bio Inc and owns about 75,668,031 shares of Translate Bio Inc (TBIO) stock worth over $2.8 Billion. Anofi is the 10% Owner of Alnylam Pharmaceuticals Inc and owns about 10,554,134 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $2.0 Billion. Anofi is also the 10% Owner of Regeneron Pharmaceuticals Inc and owns about 279,766 shares of Regeneron Pharmaceuticals Inc (REGN) stock worth over $224 Million. Besides these, Anofi also holds Icosavax Inc (ICVX) , Voyager Therapeutics Inc (VYGR) , Fulcrum Therapeutics Inc (FULC) , Inozyme Pharma Inc (INZY) , MyoKardia Inc (MYOK) . Details can be seen in Anofi 's Latest Holdings Summary section.

Transaction Summary of Anofi

Anofi Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Anofi owns 11 companies in total, including Inozyme Pharma Inc (INZY) , Regeneron Pharmaceuticals Inc (REGN) , and Fulcrum Therapeutics Inc (FULC) among others .

Click here to see the complete history of Anofi ’s form 4 insider trades.

Insider Ownership Summary of Anofi

Ticker	Comapny	Transaction Date	Type of Owner
INZY	Inozyme Pharma Inc	2020-07-23	10 percent owner
REGN	Regeneron Pharmaceuticals Inc	2014-01-27	10 percent owner
FULC	Fulcrum Therapeutics Inc	2019-07-17	10 percent owner
MYOK	MyoKardia Inc	2019-02-13	10 percent owner
ALNY	Alnylam Pharmaceuticals Inc	2016-02-01	10 percent owner
VYGR	Voyager Therapeutics Inc	2015-11-10	10 percent owner
SCYX	SCYNEXIS Inc	2014-05-07	10 percent owner
RGLS	Regulus Therapeutics Inc	2014-02-04	10 percent owner
GLYC	GlycoMimetics Inc	2013-11-06	10 percent owner
HGEN	Humanigen Inc	2012-08-11	10 percent owner
ICVX	Icosavax Inc	2021-07-28	10 percent owner

Anofi Latest Holdings Summary

Anofi currently owns a total of 8 stocks. Among these stocks, Anofi owns 75,668,031 shares of Translate Bio Inc (TBIO) as of September 14, 2021, with a value of $2.8 Billion and a weighting of 55.4%. Anofi owns 10,554,134 shares of Alnylam Pharmaceuticals Inc (ALNY) as of May 31, 2017, with a value of $2.0 Billion and a weighting of 39.4%. Anofi also owns 279,766 shares of Regeneron Pharmaceuticals Inc (REGN) as of June 9, 2020, with a value of $224 Million and a weighting of 4.4%. The other 5 stocks Icosavax Inc (ICVX) , Voyager Therapeutics Inc (VYGR) , Fulcrum Therapeutics Inc (FULC) , Inozyme Pharma Inc (INZY) , MyoKardia Inc (MYOK) have a combined weighting of 0.8100000000000001% among all his current holdings.

Latest Holdings of Anofi

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TBIO	Translate Bio Inc	2021-09-14	75,668,031	37.36	2,826,957,638
ALNY	Alnylam Pharmaceuticals Inc	2017-05-31	10,554,134	190.49	2,010,456,986
REGN	Regeneron Pharmaceuticals Inc	2020-06-09	279,766	802.16	224,417,095
ICVX	Icosavax Inc	2021-08-02	3,155,169	6.15	19,404,289
VYGR	Voyager Therapeutics Inc	2015-11-16	2,477,941	7.48	18,534,999
FULC	Fulcrum Therapeutics Inc	2019-07-22	558,035	3.14	1,752,230
INZY	Inozyme Pharma Inc	2020-07-28	520,125	3.30	1,716,413
MYOK	MyoKardia Inc	2019-02-13	0	224.91	0

Holding Weightings of Anofi

Anofi Form 4 Trading Tracker

According to the SEC Form 4 filings, Anofi has made a total of 1 transactions in Translate Bio Inc (TBIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Translate Bio Inc is the acquisition of 71,983,597 shares on September 14, 2021, which cost Anofi around $2.7 Billion.

According to the SEC Form 4 filings, Anofi has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the acquisition of 297,501 shares on May 31, 2017, which cost Anofi around $21 Million.

According to the SEC Form 4 filings, Anofi has made a total of 7 transactions in Regeneron Pharmaceuticals Inc (REGN) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in Regeneron Pharmaceuticals Inc is the sale of 120,234 shares on June 9, 2020, which brought Anofi around $72 Million.

More details on Anofi 's insider transactions can be found in the Insider Trading History of Anofi table.

Insider Trading History of Anofi

Ticker
TBIO
ICVX
INZY
REGN
REGN
REGN
REGN
FULC
REGN
MYOK
REGN
REGN
MYOK
REGN
REGN
MYOK
REGN
ALNY
REGN
MYOK

Ticker	Company	Date	Buy/Sell	Insider Trading Shares	Shares Change	Price	Cost	Final Share	Current Price	Price Change Since Insider Trade (%)	Filing Date
TBIO	Translate Bio Inc	2021-09-14	Buy	71,983,597.00	1,953.72%	$38.00	$2,735,380,000.00	75,668,031.00	$37.36	-1.68%	-
ICVX	Icosavax Inc	2021-08-02	Buy	66,667.00	2.16%	$15.00	$1,000,000.00	3,155,169.00	$6.15	-59.00%	-
INZY	Inozyme Pharma Inc	2020-07-28	Buy	81,250.00	18.51%	$16.00	$1,300,000.00	520,125.00	$3.30	-79.38%	-
REGN	Regeneron Pharmaceuticals Inc	2020-06-09	Sell	120,234.00	-30.06%	$597.48	$71,837,400.00	279,766.00	$802.16	34.26%	-
REGN	Regeneron Pharmaceuticals Inc	2020-05-29	Sell	22,821,451.00	-98.28%	$509.85	$11,635,500,000.00	400,000.00	$802.16	57.33%	-
REGN	Regeneron Pharmaceuticals Inc	2020-03-09	Sell	128,914.00	-0.55%	$489.65	$63,122,700.00	23,221,451.00	$802.16	63.82%	-
REGN	Regeneron Pharmaceuticals Inc	2019-09-10	Sell	172,904.00	-0.74%	$281.15	$48,612,000.00	23,350,365.00	$802.16	185.31%	-
FULC	Fulcrum Therapeutics Inc	2019-07-22	Buy	93,750.00	20.19%	$16.00	$1,500,000.00	558,035.00	$3.14	-80.38%	-
REGN	Regeneron Pharmaceuticals Inc	2019-03-08	Sell	131,115.00	-0.55%	$412.17	$54,041,700.00	23,523,269.00	$802.16	94.62%	-
MYOK	MyoKardia Inc	2019-02-13	Sell	4,168,899.00	-100.00%	$37.66	$157,001,000.00	0	$224.91	497.21%	-
REGN	Regeneron Pharmaceuticals Inc	2018-09-06	Sell	104,552.00	-0.44%	$406.68	$42,519,200.00	23,654,384.00	$802.16	97.25%	-
REGN	Regeneron Pharmaceuticals Inc	2018-06-08	Sell	121,601.00	-0.51%	$309.31	$37,612,400.00	23,758,936.00	$802.16	159.34%	-
MYOK	MyoKardia Inc	2018-05-25	Buy	150,000.00	3.73%	$49.00	$7,350,000.00	4,168,899.00	$224.91	359.00%	-
REGN	Regeneron Pharmaceuticals Inc	2017-08-25	Buy	72,378.00	0.30%	$481.36	$34,839,900.00	23,880,537.00	$802.16	66.64%	-
REGN	Regeneron Pharmaceuticals Inc	2017-08-24	Buy	166,415.00	0.70%	$480.93	$80,034,000.00	23,808,159.00	$802.16	66.79%	-
MYOK	MyoKardia Inc	2017-08-14	Buy	350,000.00	9.54%	$35.50	$12,425,000.00	4,018,899.00	$224.91	533.55%	-
REGN	Regeneron Pharmaceuticals Inc	2017-06-02	Buy	136,050.00	0.58%	$478.17	$65,055,000.00	23,641,744.00	$802.16	67.76%	-
ALNY	Alnylam Pharmaceuticals Inc	2017-05-31	Buy	297,501.00	2.90%	$71.87	$21,381,400.00	10,554,134.00	$190.49	165.05%	-
REGN	Regeneron Pharmaceuticals Inc	2017-01-11	Buy	87,298.00	0.37%	$369.71	$32,274,900.00	23,505,694.00	$802.16	116.97%	-
MYOK	MyoKardia Inc	2016-10-03	Buy	450,000.00	13.98%	$15.00	$6,750,000.00	3,668,899.00	$224.91	1,399.40%	-

Total 65

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Anofi Trading Performance

GuruFocus tracks the stock performance after each of Anofi 's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Anofi is -0.79%. GuruFocus also compares Anofi 's trading performance to market benchmark return within the same time period. The performance of stocks bought by Anofi within 3 months outperforms 10 times out of 22 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Anofi 's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Anofi

Average Relative Return

7.58%

Average relative return per transaction

Outperforming Transactions

41%

9 out of 22 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Relative Return(%)	6.01	-0.79	3.98	7.58	12	14.14
Relative Return to S&P 500(%)	4.28	-3.7	-3.21	-4.84	-0.17	2.8

Anofi Ownership Network

Ownership Network List of Anofi

No Data

Ownership Network Relation of Anofi

Anofi Owned Company Details

What does Inozyme Pharma Inc do?

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Who are the key executives at Inozyme Pharma Inc?

Anofi is the 10 percent owner of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include SVP & CFO Sanjay Subramanian , Interim CFO Stephen J. Dipalma , and SVP & CMO Deborah Wenkert .

Inozyme Pharma Inc (INZY) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,355,000 shares made by Longitude Capital Partners Iii, Llc , a net purchase of 1,070,000 shares made by Robert Lorne Hopfner , and a net purchase of 1,070,000 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. .

In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Inozyme Pharma Inc (INZY) were sold and 3,616,950 shares were bought by its insiders, resulting in a net purchase of 3,616,950 shares.

Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:INZY Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Regeneron Pharmaceuticals Inc do?

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Who are the key executives at Regeneron Pharmaceuticals Inc?

Anofi is the 10 percent owner of Regeneron Pharmaceuticals Inc. Other key executives at Regeneron Pharmaceuticals Inc include director & President & CEO Leonard S Schleifer , EVP & General Mgr Industrial O Van Plew Daniel P , and EVP Research Andrew J Murphy .

Regeneron Pharmaceuticals Inc (REGN) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Regeneron Pharmaceuticals Inc (REGN). Other recent insider transactions involving Regeneron Pharmaceuticals Inc (REGN) include a net sale of 14,408 shares made by Marion Mccourt , a net sale of 10,388 shares made by Robert E Landry , and a net sale of 11,353 shares made by Arthur F Ryan .

In summary, during the past 3 months, insiders sold 33,914 shares of Regeneron Pharmaceuticals Inc (REGN) in total and bought 0 shares, with a net sale of 33,914 shares. During the past 18 months, 289,085 shares of Regeneron Pharmaceuticals Inc (REGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 289,085 shares.

Regeneron Pharmaceuticals Inc (REGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:REGN Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Fulcrum Therapeutics Inc do?

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Who are the key executives at Fulcrum Therapeutics Inc?

Anofi is the 10 percent owner of Fulcrum Therapeutics Inc. Other key executives at Fulcrum Therapeutics Inc include Chief Medical Officer Santiago Arroyo , 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Ra Capital Management, L.p. .

Fulcrum Therapeutics Inc (FULC) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Fulcrum Therapeutics Inc (FULC). Other recent insider transactions involving Fulcrum Therapeutics Inc (FULC) include a net purchase of 4,609,704 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 244,705 shares made by Robert J Gould .

In summary, during the past 3 months, insiders sold 6,766 shares of Fulcrum Therapeutics Inc (FULC) in total and bought 2,107,868 shares, with a net purchase of 2,101,102 shares. During the past 18 months, 244,705 shares of Fulcrum Therapeutics Inc (FULC) were sold and 4,609,704 shares were bought by its insiders, resulting in a net purchase of 4,364,999 shares.

Fulcrum Therapeutics Inc (FULC)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:FULC Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does MyoKardia Inc do?

MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Who are the key executives at MyoKardia Inc?

Anofi is the 10 percent owner of MyoKardia Inc. Other key executives at MyoKardia Inc include director & President and CEO Anastasios Gianakakos , General Counsel Denelle J Waynick , and Chief Business Officer Jake Bauer .

MyoKardia Inc (MYOK) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of MyoKardia Inc (MYOK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MyoKardia Inc (MYOK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

MyoKardia Inc (MYOK)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:MYOK Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Alnylam Pharmaceuticals Inc do?

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Who are the key executives at Alnylam Pharmaceuticals Inc?

Anofi is the 10 percent owner of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include EVP & CLO & Secretary Indrani Lall Franchini , CMO & EVP Dev & Med Affairs Pushkal Garg , and EVP & Chief Commercial Officer Tolga Tanguler .

Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 10,374 shares made by Tolga Tanguler , a net sale of 63,670 shares made by Phillip A Sharp , and a net sale of 33,978 shares made by John Maraganore .

In summary, during the past 3 months, insiders sold 24,772 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 24,772 shares. During the past 18 months, 153,148 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 153,148 shares.

Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:ALNY Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Voyager Therapeutics Inc do?

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Who are the key executives at Voyager Therapeutics Inc?

Anofi is the 10 percent owner of Voyager Therapeutics Inc. Other key executives at Voyager Therapeutics Inc include 10 percent owner Neurocrine Biosciences Inc , Chief Scientific Officer Todd Alfred Carter , and Chief Financial Officer Peter P. Pfreundschuh .

Voyager Therapeutics Inc (VYGR) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Voyager Therapeutics Inc (VYGR). Other recent insider transactions involving Voyager Therapeutics Inc (VYGR) include a net sale of 27,856 shares made by Robert W. Hesslein , a net sale of 1,705,885 shares made by Third Rock Ventures Iii, L.p. , and a net sale of 27,155 shares made by Robin Swartz .

In summary, during the past 3 months, insiders sold 1,685,242 shares of Voyager Therapeutics Inc (VYGR) in total and bought 4,395,588 shares, with a net purchase of 2,710,346 shares. During the past 18 months, 2,699,048 shares of Voyager Therapeutics Inc (VYGR) were sold and 4,872,988 shares were bought by its insiders, resulting in a net purchase of 2,173,940 shares.

Voyager Therapeutics Inc (VYGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:VYGR Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does SCYNEXIS Inc do?

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Who are the key executives at SCYNEXIS Inc?

Anofi is the 10 percent owner of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Financial Officer Ivor Macleod , Interim CFO Lawrence R Hoffman , and Chief Commercial Officer Christine Coyne .

SCYNEXIS Inc (SCYX) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in SCYNEXIS Inc (SCYX). Other recent insider transactions involving SCYNEXIS Inc (SCYX) include a net purchase of 75,000 shares made by Marco Taglietti , and a net purchase of 3,500 shares made by Scott Sukenick .

In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 78,500 shares were bought by its insiders, resulting in a net purchase of 78,500 shares.

SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:SCYX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Regulus Therapeutics Inc do?

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Who are the key executives at Regulus Therapeutics Inc?

Anofi is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Scientific Officer Denis Drygin , 10 percent owner Sarissa Capital Master Fund Ii Lp , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net purchase of 100,000 shares made by Denis Drygin , and a net purchase of 100,000 shares made by Joseph P Hagan .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regulus Therapeutics Inc (RGLS) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:RGLS Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does GlycoMimetics Inc do?

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

Who are the key executives at GlycoMimetics Inc?

Anofi is the 10 percent owner of GlycoMimetics Inc. Other key executives at GlycoMimetics Inc include 10 percent owner Artal Group S.a. , 10 percent owner Invus Public Equities Advisors, Llc , and 10 percent owner Invus Public Equities, L.p. .

GlycoMimetics Inc (GLYC) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in GlycoMimetics Inc (GLYC). Other recent insider transactions involving GlycoMimetics Inc (GLYC) include a net purchase of 2,026,717 shares made by Invus Public Equities, L.p. , a net sale of 4,121,511 shares made by Scott D Sandell , and a net purchase of 310,000 shares made by Edwin Rock .

In summary, during the past 3 months, insiders sold 4,121,511 shares of GlycoMimetics Inc (GLYC) in total and bought 2,026,717 shares, with a net sale of 2,094,794 shares. During the past 18 months, 4,129,994 shares of GlycoMimetics Inc (GLYC) were sold and 2,512,662 shares were bought by its insiders, resulting in a net sale of 1,617,332 shares.

GlycoMimetics Inc (GLYC)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:GLYC Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Humanigen Inc do?

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Who are the key executives at Humanigen Inc?

Anofi is the 10 percent owner of Humanigen Inc. Other key executives at Humanigen Inc include 10 percent owner Black Horse Capital Lp , 10 percent owner Black Horse Capital Master Fund Ltd. , and Chief Medical Officer Adrian Kilcoyne .

Humanigen Inc (HGEN) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Humanigen Inc (HGEN). Other recent insider transactions involving Humanigen Inc (HGEN) include a net purchase of 2,042,996 shares made by Dale Chappell , a net purchase of 40,000 shares made by Cameron Durrant , and a net purchase of 12,500 shares made by Edward P. Jordan .

In summary, during the past 3 months, insiders sold 0 shares of Humanigen Inc (HGEN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Humanigen Inc (HGEN) were sold and 2,107,496 shares were bought by its insiders, resulting in a net purchase of 2,107,496 shares.

Humanigen Inc (HGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:HGEN Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Icosavax Inc do?

Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Who are the key executives at Icosavax Inc?

Anofi is the 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include See Remarks Elizabeth Bekiroglu , 10 percent owner Cormorant Private Healthcare Fund Iii Lp , and 10 percent owner Nanodimension Iii Gp Limited Partnership .

Icosavax Inc (ICVX) Insider Trades Summary

Over the past 18 months, Anofi made no insider transaction in Icosavax Inc (ICVX). Other recent insider transactions involving Icosavax Inc (ICVX) include a net sale of 18,472 shares made by Cassia Cearley , a net sale of 85,647 shares made by Adam K. Simpson , and a net sale of 34,894 shares made by Douglas Holtzman .

In summary, during the past 3 months, insiders sold 28,655 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 28,655 shares. During the past 18 months, 158,866 shares of Icosavax Inc (ICVX) were sold and 184,218 shares were bought by its insiders, resulting in a net purchase of 25,352 shares.

Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:ICVX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

Anofi Mailing Address

Above is the net worth, insider trading, and ownership report for Anofi . You might contact Anofi via mailing address: 46 Avenue De La Grande Armee, Paris I0 75017.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF ADV Part 2A ADV Part 2B ADV Part 3 Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.